Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
about
High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomenaImproved consistency in dosing anti-tuberculosis drugs in Taipei, TaiwanDosing of antibacterial agents in obese adults: does one size fit all?Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesConcentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.Hepatic safety of antibiotics used in primary careExposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosisModel-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionPreliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigsPopulation pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorptionPharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Update in tuberculosis 2007.Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.New treatment options for multidrug-resistant tuberculosis.Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome.Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.Optimizing the clinical pharmacology of tuberculosis medications.A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroThe challenges of pharmacokinetic variability of first-line anti-TB drugs.Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population is not Related to Anti-retroviral Therapy.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
P2860
Q28391941-E3B56D10-FF70-46A9-BDC4-A6591B90A17DQ28482677-CAC8B418-0A90-4B05-9B94-8017CB6B4A2EQ30362353-48FD5956-485C-4D76-B51B-0F88FD018244Q30498213-4ACE9D91-A762-4EAF-A78C-1A4C043EDF85Q30834393-E66614F0-4F74-43E9-8334-B68B76778902Q33521011-BBEF0E3D-ED78-4AD7-AF4A-5B62027B568DQ33621748-A353490F-4271-4857-9E60-40AAC7661237Q33676191-59635554-5CFE-43FA-B1CA-2D0C40B38FA3Q34729493-73E3D1D3-C696-40E8-9F32-836561984EFFQ35028452-19804EA7-61EA-4C53-BDE5-468527285F2FQ35037383-5ADDDD08-C8CC-4FBB-8F97-43F78791628DQ35584822-DDB6DF62-984C-4488-9CD7-B05AAD6A582BQ35598492-27A783AB-4303-4E0A-AD4F-3DDCE41EAF3BQ35859862-444C4E53-4C33-4A6A-8DC4-6BD8D5A72501Q35867681-4F2D4921-3B00-4C3B-8002-45A32B00188CQ35978007-85CCC36F-78D8-4306-B753-16AF818F53ADQ36171524-2254D949-D7C8-4772-9EE4-BBDF4945A521Q36438900-6AC69F02-995A-4EB8-9FA7-C84F5D6BCCC8Q36667095-FED559A6-6B94-4A6B-BE0E-E038863CF69CQ36702972-A83E277A-DA5B-4BDA-8797-B3B500D0339AQ36969720-1DE70041-52BA-43EA-8338-A9C4ECC97690Q37036489-EAA051AD-0924-42C0-842E-8EB295345E4EQ37093439-27CCCB01-056C-4D76-AB86-3B34795E9E85Q37247736-E1256D5C-6ADD-4DE6-A330-F4463A0698FEQ37346929-54CBF73F-8C7B-4AC8-B1C5-E19B03665487Q38024041-B0642102-0F2B-4DE8-8B7C-C259B1C33190Q38041192-E216B182-1D7F-4D9B-89AF-CE2C13BE008AQ38244769-AF5A1E4B-6349-4D8C-8395-9980B7890D55Q38542159-DEE491E6-9EDB-4E11-967E-74F3BA0733B7Q38666266-A55C3023-E5FD-4B4D-8F2D-F1FB623BDBC9Q38724073-69BA5D1B-3D60-435B-A5F7-DB594C6C52C0Q38851516-86FBD3AC-5803-4113-B51A-935B30263C70Q38852090-6340A104-ABBB-418F-8A17-1D5014E13BCCQ38963389-0D39FEDA-C644-47C9-BEB9-587A68EB72C2Q38977166-4818050C-4EFE-40B3-8140-BD191A61057EQ39062681-568B0D3F-0BCC-4D85-A8E8-35A43B5342FAQ39539828-F4B6D26E-4135-4001-8856-FC65451F2F35Q40155324-73DD0456-8B68-44BF-93C0-37FB3C977922Q40192322-1248D8D4-D372-4644-B5FA-595967510777Q40441668-35835BD1-4080-42BB-9283-335A2FFC5C51
P2860
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@ast
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@en
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@nl
type
label
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@ast
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@en
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@nl
prefLabel
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@ast
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@en
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@nl
P2093
P2860
P50
P356
P1476
Pharmacokinetics and tolerabil ...... lmonary tuberculosis patients.
@en
P2093
Hanneke M J Nijland
Rob E Aarnoutse
Rovina Ruslami
P2860
P304
P356
10.1128/AAC.01550-06
P407
P577
2007-04-23T00:00:00Z